TORONTO--(BUSINESS WIRE)--Cybin, Canada's premier medicinal mushroom life sciences company with a core focus on advancing psilocybin research and intellectual property is pleased to announce a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS).
Some of the first academic research available on microdosing was published by the Toronto Centre for Psychedelic Science (TCPS) via its co-founders, Rotem Petranker and Thomas Anderson. Both gentlemen have also been appointed as exclusive clinical advisors to Cybin and will be working alongside the company on all Canadian clinical initiatives.
Cybin is working towards building a vast intellectual property portfolio. The IP is structured around unique psilocybin delivery mechanisms that target certain indications. Key partnerships with esteemed individuals and institutions who share the same vision will assist in the acceleration of Cybin's goals.
"While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach," says Paul Glavine, CEO of Cybin. "We are delighted to join the Centre on this journey," Glavine adds.
"We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigour and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad," says Thomas Anderson, Co-founder of the Toronto Centre for Psychedelic Science.
“I am excited for this collaboration, which will explore the huge potential for benefiting mankind," says Rotem Petranker, Co-founder of the Toronto Centre for Psychedelic Science.
About Cybin Corp
Cybin Corp is a Mushroom Life Sciences company advancing psychedelic and medicinal mushroom research, product development and IP through a multi-tiered pharmaceutical and nutraceutical approach.
The company is launching psilocybin-based products in jurisdiction’s where the substance is not banned alongside structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.
About Rotem Petranker
- Associate Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto
- Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing
- BSc in psychology from the University of Toronto and an MA in social psychology from York University while currently undergoing his PhD candidacy at York University
- Main research interests include sustained attention, emotion regulation and creativity which are ostensibly affected by psychedelics. Clinical interests include disorders amenable to psychedelic psychotherapy, including mood disorders and obsessive compulsive disorder
- Rotem is passionate about establishing a rigorous framework for the study of psychedelics using the principles of Open Science
About Thomas Anderson
- Research Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto
- Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing
- PhD candidate and cognitive neuroscientist with the Regulatory and Affective Dynamics (RAD) Lab of Norman Farb, an associate professor of psychology at U of T Mississauga
- Thomas’ research is some of the first on psychedelic microdosing
- Supported by the Natural Sciences and Engineering Council of Canada (NSERC) and the Stratas Foundation which recently award Thomas with an innovation award
- Published scholarly articles on attention, meditation, psychedelics, and neuroimaging and has a strong commitment to open science, rigour, and transparency
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements.
Additional factors that could cause actual results, performance or achievements to differ materially. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Cybin. These forward-looking statements are made as of the date of this press release and Cybin assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.
